Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes

NCT ID: NCT04625751

Last Updated: 2024-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-07

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is a growing global health care challenge. Diabetes patients may also suffer from cardiovascular autonomic neuropathy (CAN) which may affect cerebral perfusion. The main purpose of this project is to investigate the association between CAN and disturbances in the neurovascular coupling in type 2 diabetes patients. Moreover, the purpose is also to investigate coherence between CAN and the enteric nervous system. Finally, this project aims at delineating microstructural changes in the brain tissues as a consequence of CAN.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Cardiovascular Autonomic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T2DM +CAN

CO2-enriched air

Intervention Type OTHER

To assess cardiovascular reactivity

Meal response test

Intervention Type OTHER

Meal response test to assess changes in splanchnic blood flow.

T2DM -CAN

CO2-enriched air

Intervention Type OTHER

To assess cardiovascular reactivity

Meal response test

Intervention Type OTHER

Meal response test to assess changes in splanchnic blood flow.

Healthy control

CO2-enriched air

Intervention Type OTHER

To assess cardiovascular reactivity

Meal response test

Intervention Type OTHER

Meal response test to assess changes in splanchnic blood flow.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CO2-enriched air

To assess cardiovascular reactivity

Intervention Type OTHER

Meal response test

Meal response test to assess changes in splanchnic blood flow.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of type 2 diabetes (Patients)
* Age between 50-70 years (All)
* Presence of CAN as diagnosed by cardiovascular reflex tests with two or three pathological results (Patients with CAN only)
* Exclusion of CAN as diagnosed by cardiovascular reflex tests with no pathological results (Patients without CAN and HC only)

Exclusion Criteria

* Participants receiving treatment with direct effects on noradrenergic or cholinergic signaling (for example beta-blockers, tricyclic antidepressants, SSRI's) (All)
* Acute infections (All)
* Thyroid disease (All)
* Substance or alcohol abuse (All)
* Atrial fibrillation or flutter (All)
* Respiratory failure (All)
* Participants in active laser treatment for retinopathy, will be excluded from the Valsalva test (Patients)
* Non-diabetic causes of neuropathy including a medical history of vitamin B12 deficiency, folic acid deficiency, rheumatoid arthritics, amyloidosis, HIV, syphilis, Borreliosis, drug induced neuropathy and neuropathy caused by toxins (All)
* Claustrophobia (All)
* Implanted pacemakers or remaining pacemaker electrodes (All)
* Previous heart or brain surgery with use of metal clips (All)
* Any form of non-MR-compatible implants
* Non-compliance with the study protocol as judged by the investigators (All)
* Concurrent participation in an intervention study (Patients)
* Participants who by judgments of the investigator, is incapable of participating (All)
Minimum Eligible Age

50 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Steno Diabetes Center Copenhagen

OTHER

Sponsor Role collaborator

Hartwig R. Siebner

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hartwig R. Siebner

Professor, DMSc

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hartwig R. Siebner, MD, Prof

Role: PRINCIPAL_INVESTIGATOR

Danish Research Centre for Magnetic Resonance

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Steno Diabetes Center Copenhagen

Gentofte Municipality, , Denmark

Site Status

Danish Research Centre for Magnetic Resonance

Hvidovre, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-20031245

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Type 1 Diabetes Autonomic and Vascular Function
NCT06786546 ENROLLING_BY_INVITATION
Renal Denervation in Diabetes.
NCT02081989 WITHDRAWN PHASE4